|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GALNT15 |
Gene summary for GALNT15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GALNT15 | Gene ID | 117248 |
| Gene name | polypeptide N-acetylgalactosaminyltransferase 15 | |
| Gene Alias | GALNACT15 | |
| Cytomap | 3p25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | C9JGI4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 117248 | GALNT15 | HCC1 | Human | Liver | HCC | 1.17e-09 | 7.53e-01 | 0.5336 |
| 117248 | GALNT15 | HCC2 | Human | Liver | HCC | 3.58e-20 | 1.25e+00 | 0.5341 |
| 117248 | GALNT15 | HCC5 | Human | Liver | HCC | 4.92e-25 | 1.30e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GALNT15 | insertion | Nonsense_Mutation | novel | c.1913_1914insGTTTCTGGGAGGAGGGAGGAATGGGGAGTGACTGCTGATGGAC | p.Arg639PhefsTer10 | p.R639Ffs*10 | Q8N3T1 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| GALNT15 | SNV | Missense_Mutation | novel | c.1505G>T | p.Arg502Met | p.R502M | Q8N3T1 | protein_coding | deleterious(0.01) | benign(0.023) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GALNT15 | SNV | Missense_Mutation | c.307N>A | p.Gln103Lys | p.Q103K | Q8N3T1 | protein_coding | tolerated(0.2) | benign(0) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GALNT15 | SNV | Missense_Mutation | c.308N>G | p.Gln103Arg | p.Q103R | Q8N3T1 | protein_coding | tolerated(1) | benign(0) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GALNT15 | SNV | Missense_Mutation | c.599N>G | p.His200Arg | p.H200R | Q8N3T1 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GALNT15 | SNV | Missense_Mutation | rs142616039 | c.1160N>T | p.Ser387Leu | p.S387L | Q8N3T1 | protein_coding | tolerated(0.23) | benign(0.011) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| GALNT15 | SNV | Missense_Mutation | c.1515N>A | p.Phe505Leu | p.F505L | Q8N3T1 | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| GALNT15 | SNV | Missense_Mutation | rs773183021 | c.92C>T | p.Ala31Val | p.A31V | Q8N3T1 | protein_coding | tolerated_low_confidence(0.09) | benign(0.017) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| GALNT15 | SNV | Missense_Mutation | rs756197962 | c.1886N>A | p.Arg629His | p.R629H | Q8N3T1 | protein_coding | tolerated(0.3) | benign(0) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| GALNT15 | SNV | Missense_Mutation | c.1066N>G | p.Ile356Val | p.I356V | Q8N3T1 | protein_coding | tolerated(0.42) | benign(0.003) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |